With new questions emerging about the strength of the economy, will there be a potential cut in dividends? The "Fast Money Halftime Report" traders discuss.
CNBC's Jim Cramer explains why he is watching Celgene.
Jim Cramer explains what to watch ahead of the open including Ionis Pharmaceuticals and Biogen.
CNBC's Meg Tirrell reports on Theranos founder Elizabeth Holmes making her first public appearance since getting banned from operating a clinical lab.
GlaxoSmithKline and Alphabet's life sciences unit are creating a new company focused on fighting diseases.
The "Fast Money Halftime Report" panel joined by CNBC's Meg Tirrell discuss the future of microbiome medicine.
UK pharma giant records net loss for the second quarter but is set to gain from export-driven growth.
Andrew Witty, CEO of GlaxoSmithKline, says the firm has been investing in bio electronic medicine for the last few years.
CNBC's Bob Pisani looks at the day's market action, earnings, and why things seem to be holding up so well.
Greg Sarian, Hightower, says he favors the biotech sector right now.
Big drug discoveries have been scant, but investors can find long-term value in some biotech names, said Mark Schoenebaum of Evercore ISI.
Today's bell ringers are Jung-ho Shin, Chief Global Officer of Line Corporation, at the NYSE; and Jeffrey Bacha, Chairman & CEO of Delmar Pharmaceuticals, at the Nasdaq.
The "Fast Money traders debate the case for the Nasdaq to make a record high alongside the Dow and S&P 500.
The FDA has put a clinical hold on a phase 2 clinical trial of one of its products after two patients died last week.
CNBC's Meg Tirrell discusses biotech in the bear market and what to expect going forward.
CNBC's Meg Tirrell reports on the health of the biotech sector and what could spur a turnaround in the second half of the year.
The iShares NASDAQ Biotechnology ETF was up more than 3 percent on the week, but down nearly 24 percent this year.
CNBC's Meg Tirrell reports on the bounce in the biotech sector and how some names could be a good buy at the moment.
CNBC's Meg Tirrell tracks the IBB, which is getting a boost from a new report on the health of Medicare.
The Hollywood actress will play the role of Theranos CEO Elizabeth Holmes on the big screen.